Quantification of trace 227Ac and other radionuclidic impurities in mass-separated 225Ac samples produced at CERN-MEDICIS
Abstract 225Ac is a promising candidate medical radionuclide for targeted alpha therapy of advanced stage cancers. One of the main production pathways is the high-energy proton spallation of thorium-based targets, that requires an efficient, nuclide-selective separation method to recover 225Ac from...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-02277-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849768883801554944 |
|---|---|
| author | Jake D. Johnson Cyril Bernerd Frank Bruchertseifer Thomas E. Cocolios Marie Deseyn Charlotte Duchemin Michael Heines Max Keppens Laura Lambert Nathan Meurrens Ralf E. Rossel Thierry Stora Viktor Van den Bergh |
| author_facet | Jake D. Johnson Cyril Bernerd Frank Bruchertseifer Thomas E. Cocolios Marie Deseyn Charlotte Duchemin Michael Heines Max Keppens Laura Lambert Nathan Meurrens Ralf E. Rossel Thierry Stora Viktor Van den Bergh |
| author_sort | Jake D. Johnson |
| collection | DOAJ |
| description | Abstract 225Ac is a promising candidate medical radionuclide for targeted alpha therapy of advanced stage cancers. One of the main production pathways is the high-energy proton spallation of thorium-based targets, that requires an efficient, nuclide-selective separation method to recover 225Ac from hundreds of co-produced spallation and fission products. The main radioactive contaminant of concern is 227Ac (T1/2 = 21.8 years), that could preclude extensive medical use if not significantly suppressed. In this work, 225Ac samples were produced by mass separation of radioactive ion beams extracted from proton-irradiated thorium-based targets. The activity of 225Ac and other possible contaminants of the samples were measured using complementary gamma- and alpha-decay spectrometry methods, while 227Ac activity was calculated by performing alpha-decay spectrometry of recoiled progeny from the sample. Using this novel method, accurate measurement of trace 227Ac activity in 225Ac samples was performed much faster than with conventional spectrometry techniques, thanks to its 10,000-fold increase in relative sensitivity. The end of collection activity ratio of 227Ac to 225Ac in two samples from irradiated targets were determined to be $$2.00(10) \times 10^{-6}$$ and $$2.7(4) \times 10^{-6}$$ respectively, three orders of magnitude below the 227Ac activity in 225Ac products obtained through radiochemical separation. The high separation factor of 225Ac over 227Ac suggests the suitability of mass-separated accelerator-based 225Ac for medical use. |
| format | Article |
| id | doaj-art-3e9b5e3568884d19b5d2f099afe6eb5e |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-3e9b5e3568884d19b5d2f099afe6eb5e2025-08-20T03:03:40ZengNature PortfolioScientific Reports2045-23222025-07-0115111410.1038/s41598-025-02277-4Quantification of trace 227Ac and other radionuclidic impurities in mass-separated 225Ac samples produced at CERN-MEDICISJake D. Johnson0Cyril Bernerd1Frank Bruchertseifer2Thomas E. Cocolios3Marie Deseyn4Charlotte Duchemin5Michael Heines6Max Keppens7Laura Lambert8Nathan Meurrens9Ralf E. Rossel10Thierry Stora11Viktor Van den Bergh12KU Leuven, IKSKU Leuven, IKSJRCKU Leuven, IKSKU Leuven, IKSKU Leuven, IKSKU Leuven, IKSKU Leuven, IKSCERNKU Leuven, IKSCERNCERNKU Leuven, IKSAbstract 225Ac is a promising candidate medical radionuclide for targeted alpha therapy of advanced stage cancers. One of the main production pathways is the high-energy proton spallation of thorium-based targets, that requires an efficient, nuclide-selective separation method to recover 225Ac from hundreds of co-produced spallation and fission products. The main radioactive contaminant of concern is 227Ac (T1/2 = 21.8 years), that could preclude extensive medical use if not significantly suppressed. In this work, 225Ac samples were produced by mass separation of radioactive ion beams extracted from proton-irradiated thorium-based targets. The activity of 225Ac and other possible contaminants of the samples were measured using complementary gamma- and alpha-decay spectrometry methods, while 227Ac activity was calculated by performing alpha-decay spectrometry of recoiled progeny from the sample. Using this novel method, accurate measurement of trace 227Ac activity in 225Ac samples was performed much faster than with conventional spectrometry techniques, thanks to its 10,000-fold increase in relative sensitivity. The end of collection activity ratio of 227Ac to 225Ac in two samples from irradiated targets were determined to be $$2.00(10) \times 10^{-6}$$ and $$2.7(4) \times 10^{-6}$$ respectively, three orders of magnitude below the 227Ac activity in 225Ac products obtained through radiochemical separation. The high separation factor of 225Ac over 227Ac suggests the suitability of mass-separated accelerator-based 225Ac for medical use.https://doi.org/10.1038/s41598-025-02277-4 |
| spellingShingle | Jake D. Johnson Cyril Bernerd Frank Bruchertseifer Thomas E. Cocolios Marie Deseyn Charlotte Duchemin Michael Heines Max Keppens Laura Lambert Nathan Meurrens Ralf E. Rossel Thierry Stora Viktor Van den Bergh Quantification of trace 227Ac and other radionuclidic impurities in mass-separated 225Ac samples produced at CERN-MEDICIS Scientific Reports |
| title | Quantification of trace 227Ac and other radionuclidic impurities in mass-separated 225Ac samples produced at CERN-MEDICIS |
| title_full | Quantification of trace 227Ac and other radionuclidic impurities in mass-separated 225Ac samples produced at CERN-MEDICIS |
| title_fullStr | Quantification of trace 227Ac and other radionuclidic impurities in mass-separated 225Ac samples produced at CERN-MEDICIS |
| title_full_unstemmed | Quantification of trace 227Ac and other radionuclidic impurities in mass-separated 225Ac samples produced at CERN-MEDICIS |
| title_short | Quantification of trace 227Ac and other radionuclidic impurities in mass-separated 225Ac samples produced at CERN-MEDICIS |
| title_sort | quantification of trace 227ac and other radionuclidic impurities in mass separated 225ac samples produced at cern medicis |
| url | https://doi.org/10.1038/s41598-025-02277-4 |
| work_keys_str_mv | AT jakedjohnson quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis AT cyrilbernerd quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis AT frankbruchertseifer quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis AT thomasecocolios quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis AT mariedeseyn quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis AT charlotteduchemin quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis AT michaelheines quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis AT maxkeppens quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis AT lauralambert quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis AT nathanmeurrens quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis AT ralferossel quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis AT thierrystora quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis AT viktorvandenbergh quantificationoftrace227acandotherradionuclidicimpuritiesinmassseparated225acsamplesproducedatcernmedicis |